Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Cohort Study of LORLATINIB-related HYPERLIPIDEMIA in ALK+ Advanced Non-Small Cell Lung Cancer Patients

NCT06876675 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT06876675
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06876675 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Cohort Study of LORLATINIB-related HYPERLIPIDEMIA in ALK+ Advanced Non-Small Cell Lung Cancer Patients
Lead sponsor
Peking University Third Hospital
Phase
Observational
Overall status
Enrolling by invitation
Start date
October 15, 2024
Completion date
August 31, 2029
Enrollment
167 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hyperlipidemia, non-small cell lung cancer